Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.

Zoledronate, a potent third-generation amino-bisphosphonate previously used for the treatment of bone metastasis, was recently shown to significantly reduce the risk of vertebral and hip fractures in osteoporotic postmenopausal women when infused at a dose of 5 mg per year for 3 years. The renal follow-up of this pivotal study that included more than 5,000 patients (estimated creatinine clearance >30 ml per min) is reported by Boonen et al. and shows the long-term renal safety of zoledronate in this osteoporotic population.